asunaprevir + daclatasvir + ribavirin + peginterferon alfa-2a

This is a four-drug combination regimen consisting of asunaprevir, daclatasvir, ribavirin, and peginterferon alfa-2a. It is used primarily for the treatment of chronic hepatitis C virus (HCV) infection, particularly in patients with genotype 1 or 4 who have previously failed therapy with peginterferon and ribavirin alone[2][5]. - **Asunaprevir** is an NS3 protease inhibitor that blocks viral replication by inhibiting the HCV NS3/4A protease. - **Daclatasvir** is a potent pangenotypic NS5A inhibitor that interferes with viral RNA replication and virion assembly[5]. - **Ribavirin** is a nucleoside analog antiviral that inhibits viral RNA synthesis. - **Peginterferon alfa-2a** is a recombinant interferon that stimulates host immune responses against HCV by binding to type I interferon receptors and activating antiviral pathways[6]. The combination has demonstrated high sustained virological response (SVR) rates in clinical trials for both genotype 1 and genotype 4 HCV infections, including in prior nonresponders to standard therapy[2][5]. The regimen was developed during the era before widespread use of all-oral direct acting antivirals.

Brand names

None for the specific four-drug combination

Other names

asunaprevir + daclatasvir + pegylated interferon alpha-2a + ribavirinasunaprevir/daclatasvir/peginterferon alfa-2a/ribavirin